MWM
BMRN icon

Mascoma Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mascoma Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed – – 111
2019
Q2 		$0 Hold
1
– – ﹤0.01% 382
2019
Q1 		$0 Hold
1
– – ﹤0.01% 394
2018
Q4 		$0 Buy
+1
New +$95 ﹤0.01% 374

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Mascoma Wealth Management's BMRN Position: Q3 2019 in Review

Mascoma Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 1 share.

Mascoma Wealth Management first reported a position in BMRN in Q4 2018 and held it in 3 quarters. The position peaked at $0 in Q2 2019. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Mascoma Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Mascoma Wealth Management sold 1 BioMarin Pharmaceuticals share in Q3 2019.
  • Mascoma Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Mascoma Wealth Management's BioMarin Pharmaceuticals position peaked at $0 in Q2 2019.
  • 437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Mascoma Wealth Management's 13F filing for Q3 2019, filed 21 Nov 2019.